Fairfax Media network navigation

  • Home
  • Shares
  • Share details

CLINUVEL PHARMACEUTICALS LIMITED (CUV)


Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today » it's FREE! Already a member? Login now!


General Information
Company Name: Clinuvel Pharmaceuticals Limited
Stock Code: CUV
Website: www.clinuvel.com
GICS Sub-Industry: Biotechnology
Market Cap ($M): 73
Equiv. Shares (M): 38

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
 $ 1.900 $ 1.900 $ 1.900 $ 1.900 $ 1.950 5,134 $ -0.050  -2.564 %

Current Broker Consensus Recommendation more
Recommendation: Buy
Recommendation Date: 5th Feb 2010
12 Month Target Price (average): $0.78
Brokers Surveyed: 1

Company Overview

Business Description:
Clinuvel Pharmaceuticals Limited (CUV) is a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. CUV’s lead compound is SCENESSE (afamelanotide), a drug targeting erythropoietic protoporphyria (EPP). Another melanocortin drugs in development is CUV9900. Based in Melbourne, Australia, CUV has operation in Europe and the US.

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2012  A -9.9 -32.3 -- 0.0 0.0 0.0 --
2011  A -12.4 -40.9 -- 0.0 0.0 0.0 --
2010  A -11.5 -38.0 -- 0.0 0.0 0.0 --
Source: Aspect actuals / Thomson IBES estimates

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2010 A 2011 F 2012 F 2010 A 2011 F 2012 F 2010 A 2011 F 2012 F
CSL (CSL) $30,453 M 0.0878 0.3215 0.1438 32.6608 24.7155 21.6080 0.0135 0.0170 0.0192
Clinuvel Pharmaceuticals (CUV) $75 M -- -- -- -- -- -- 0.0000 -- --
Mesoblast (MSB) $1,716 M -- -- -- -- -- -- 0.0000 0.0000 0.0000
Starpharma (SPL) $237 M -- -- -- -- -- -- 0.0000 0.0000 0.0000
Sirtex Medical (SRX) $606 M 0.4803 0.9043 0.3573 35.9603 18.8837 13.9124 0.0092 0.0176 0.0235

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
CUV -- -- 4.83 -- 80.9
Market 1.13 13.2 0.92 2.50 2.58
Sector 0.65 21.3 2.39 0.55 6.49

Directors
Name Position Start Date
Dr Philippe Wolgen Chief Executive Officer,Managing Director 01 October 2005
Mr Stanley McLiesh Non-Executive Chairman 12 September 2002
Ms Brenda Mary Shanahan Non-Executive Director 06 February 2007
Mr Lawrence John (Jack) Wood Non-Executive Director 08 July 2008
Mr Elie Ishag Non-Executive Director 01 February 2011

Management
Name Position
Darren Keamy Chief Finance Officer,Company Secretary
Dennis Wright Vice President, Scientific Affairs

Calendar of Events
Date Event
26 February 2014 Report (Interim)
18 October 2013 Report (Annual)
28 August 2013 Report (Prelim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg.asp.

Advertisement

Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Investing in Art

An educational booklet with useful, practical tips to help you make better-informed decisions about investing in art.

More details...

News

Plummeting dollar, budget steal limelight

The Age 18/05/2013 | The sharemarket lost ground this week, slipping 0.6 per cent, but the dollar stole the headlines after dropping like an anvil.

Break-up could breathe new life into News

The Age 18/05/2013 | Analysts say the split into two divisions may lead to a re-rating of the embattled publishing business, writes Colin Kruger.

Wesfarmers shares fall short of their Target

The Age 18/05/2013 | Wesfarmers shares suffered their biggest fall in almost two years after sharply lowering Target's earnings forecast.

China the new competitor in Australia's online sales

The Age 18/05/2013 | As Australia's major retailers increase their online sales channels, pouring millions into their websites, they could face new competition from China's booming e-commerce industry.

China roars along e-tailing superhighway

The Age 18/05/2013 | Mass consumption is coming of age in the internet era, write Richard Cooper and Richard Dobbs.

Delayed return to surplus no worry - what causes it is

The Age 18/05/2013 | Most of those who take a political approach to the budget assume that if it's in deficit, the way you get it back to surplus is to cut government spending or, if you're a really bad person, increase taxes. They forget it's the budget itself that's supposed to do the heavy lifting.

More...

Sponsored Links
Feedback Form